Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Acquisitions, Divestitures, Research Collaborations and License Agreements - Narrative (Details) - USD ($) $ in Millions	1 Months Ended
	Mar. 31, 2017	Jan. 31, 2016	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]
Goodwill	$ 18,358		$ 18,162
Contingent consideration	$ 925		$ 891	$ 652	$ 590
Vallee SA
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]
Percentage of business acquired (as percent)	93.50%
Cash paid for acquisition of business	$ 358
Escrow deposit	176
Intangible assets	297
Deferred tax liabilities noncurrent	95
Other net assets	1
Noncontrolling interest	25
Contingent liabilities	37
Indemnification assets	37
Goodwill	$ 180
Discount rate (as percent)	15.50%
Acquired finite-lived intangible assets, weighted average useful life	15 years
IOmet Pharma Ltd
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]
Cash paid for acquisition of business		$ 150
Goodwill		$ 57
Discount rate (as percent)		10.50%
Amount of potential future additional payments for milestones, maximum		$ 250
Contingent consideration		94
In-process research and development (IPR&D)		155
Deferred tax assets noncurrent		$ 32